



**LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES
CORE PHARMACY & THERAPEUTICS COMMITTEE**

September 1, 2016

TO: DHS Core P&T Committee
MHLA Clinics

FROM: Amy Gutierrez, Pharm.D.
Jeffrey Guterman, M.D.
Chairs, DHS Core Pharmacy and Therapeutics Committee

RE: August 2016 MHLA Formulary Decisions

MY HEALTH LA FORMULARY

New Drug Additions

Drug Product	Comments
Insulin Detemir (Levemir®) 100units/mL injection	Added to MHLA 340B Formulary Restricted to continuation of therapy ONLY - Insulin NPH available as first line agent
Naltrexone HCl 50 mg tablets	Added to MHLA 340B Formulary
Disulfiram (Antabuse®) 250 mg, 500mg tablets	Added to MHLA 340B Formulary
Naloxone 0.4mg/mL injectable (2 doses per kit)	Added to MHLA 340B Formulary Quantity limit of one claim per year Restricted to history of opioid drug abuse or Morphine Equivalents (MED) per day >100 <i>DHS Naloxone Expected Practices Pending (will distribute once available)</i>

Formulary Changes

Drug Product	Comments
Hydrocortisone 1% cream/ointment	Moved to MHLA OTC2 Formulary
Meclizine 25 mg tablet	Moved to MHLA OTC2 Formulary
Acetaminophen 500 mg tablet	Moved to OTC2 Formulary QL: Maximum of one claim per month with max of 100 tablets per month
Bacitracin ointment	Moved to MHLA OTC2 Formulary

Drug Deletions

Drug Product	Comments
Hydrocortisone 2.5% cream/ointment	Alternatives available on the MHLA Formulary

This document contains confidential information intended for Los Angeles County and MHLA health professionals/employees only. Unintended recipients may not disclose, copy, distribute, or take any action based on this document. This information is not to be disclosed to pharmaceutical representatives, press, or other outside agents.